SEPs N30 amplitude in Parkinson's disease and in pharmacologically induced rigidity: Relationship with the clinical status

European Journal of Neurology

Volumn 4, Issue 1, 1997, Pages 24-38

  Stanzione, P ^a,b   Traversa, R ^a   Pierantozzi, M ^b   Semprini, R ^a   Loberti, M ^b   Peppe, A ^a   Santilli, A M ^b   Bernardi, G ^a,b  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Apomorphine; Bradykinesia; Dopamine physiology; Levodopa; Neuroleptics; Parkinson's disease; Rigidity; Somatosensory evoked potentials

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; LEVODOPA;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EVOKED SOMATOSENSORY RESPONSE; FEMALE; HUMAN; INFANT; MALE; MUSCLE RIGIDITY; NEWBORN; PARKINSON DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031018603     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.1997.tb00296.x     Document Type: Article

References (23)

1. Abbruzzese G, Tabaton M, Morena M, Dall" Agata D and Favale E (1991) Motor and sensory evoked potentials in progressive sopranuclear palsy. Movement Disorder, 6, 49-54.
2. Chan-Palay V and Asan E (1989) Alteration in cathecolaminergic neurons of the locus coeruleus in senile dementia of the Alzheimer type in Parkinson's Disease with and without Dementia and depression. Journal of Comparative Neurology, 287, 373-392.
3. Cheron G and Borestein S (1987) Specific gating of the early somatosensory evoked potentials during active movement. Electroencephalography and Clinical Neurophysiology, 67, 537-548.
4. Cheron G and Borestein S (1991) Gating of the early components of the frontal and parietal somatosensory evoked potentials in different sensory-motor interfence modalities. Electroencephalography and Clinical Neurophysiology, 80, 522-530.
5. Cheron G, Piette T, Thiriaux A, Jacquy J and Godaux E (1994) Somatosensory evoked potentials at rest and during movement in Parkinson"s disease: evidence for a specific apomorphine effect on the frontal N30 wave. Electroencephalography and Clinical Neurophysiology, 92, 491-501.
6. Choen LG and Starr A (1987) Localization, timing and specificity of gating of somatosensory evoked potentials during active movement in man. Brain, 110, 451-467.
7. Fahn S, Elton RL and the Unified Rating Scale Development Committee (1987) In: Recent Development in Parkinson's Disease, V2 (Eds Fahn S, Marsden CD, Calne D and Goldstein M) pp. 153-163, 293-304. Florhan Park NJ: McMillan Healthcare Information.
8. Forsman A and Ohman R (1977) Applied pharmacokinetics of haloperidol in man. Current Therapy Research, 21, 396-411.
9. Hoehn MM and Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology, 17, 427-442.
10. Hughes AJ, Lees AJ, Kempster PA and Stern GM (1990) Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet, 1, 1262-1263.
11. Huttunen J and Homberg V (1991) Modification of the cortical somatosensory evoked potentials during tactile exploration and simple active and passive movements. Electroencephalography and Clinical Neurophysiology, 81(3), 216-223.
12. Huttunen J and Teravainen H (1993) Pre and post-central cortical somatosensory evoked potentials in hemiparkinsonism. Movement Disorder, 8(4), 430-436.
13. Jones SJ, Halonen JP and Shawkat F (1989) Centrifugal and centripetal mechanisms involved in the "gating" of the cortical SEPs during movement. Electroencephalography and Clinical Neurophysiology, 74, 36-45.
14. Mauguiere F, Broussolle E and Isnard J (1993) Apomorphine-induced relief of the Akinetic-rigid syndrome and Early median nerve somatosensory evoked potentials (SEPs) in Parkinson's Disease. Electroencephalography and Clinical Neurophysiology, 88, 242-254.
15. Nakashima K, Nitta T and Takahashi K (1992) Recovery functions of Somatosensory Evoked Potentials in parkinsonian patients. Journal of Neurological Science, 108, 24-31.
16. Onofrj M, Fulgente T, Malatesta G, Ferracci F, Thomas A, Curatola L, Bollettini F and Ragno M (1995) The abnormality of N30 somatosensory evoked potential in idiopathic Parkinson"s Disease is unrelated to disease stage or clinical scores and insensitive to dopamine manipulations. Movement Disorder, 10, 71-80.
17. Pinto F, Ragazzoni A, Amantini A, De Scisciolo G, Bartelli R, Rossi R and Pieraccioli E (1990) Anaesthetic induction with thiopental: its effect on scalp topography of median nerve somatosensory evoked potentials. Acta Anesthesiological Scandinava, 34, 389-392.
18. Rossini PM, Babiloni F, Bernardi G, Cecchi L, Johnson PB, Malentacca A, Stanzione P and Urbano A (1989) Abnormalities of short-latency Somatosensory Evoked Potentials in parkinsonian patients. Electroencephalography and Clinical Neurophysiology, 74, 277-289.
19. Rossini PM, Paradiso C, Zarola F, Mariorenzi R, Traversa R, Martino G and Caramia MD (1990) Bit-mapped somatosensory evoked potentials and muscular reflex responses in man: comparative analysis in different experimental protocols. Electroencephalography and Clinical Neurophysiology, 77, 266-275.
20. Rossini PM, Traversa R, Boccasena P, Martino G, Passarelli F, Pacifici L, Bernardi G and Stanzione P (1993) Parkinson"s Disease and Somatosensory Evoked Potentials: Apomorphine induced transient potentiation of frontal components. Neurology, 43, 2495-2500.
21. Rossini PM, Bassetti MA and Pasqualetti P (1995) Median nerve somatosensory evoked potentials, apomorphine-induced transient potentiation of frontal components in Parkinson"s disease and in parkinsonism. Electroencephalography and Clinical Neurophysiology, 96, 236-247.
22. Stanzione P, Tagliati M, Silvestrini M, Porcu S and Bernardi G (1991) Haloperidol delays electroretinograms more than visual evoked potentials in normal Humans: a pharmacological tool in Parkinson" s disease pathophysiology. Clinical Visual Science, 6, 137-147.
23. Stibe C, Lees A and Stern G (1987) Subcutaneus infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations. Lancet, 1, 871.